Company News & Press
22 June 2020
OMNImet™·GUT expands access to critical metabolomic analysis with development of in-home fecal collection device – the first device for in-home collection and ambient-temperature storage and shipping of fecal samples for metabolomics, to the research market.
17 June 2020
“One of the unique characteristics of metabolomics is its ability to reveal functionality. This is of great benefit as it can help to fill the gaps of other ’omics where insights may be lacking. Scientists can use metabolomics to provide a bridge with other ’omic approaches to more completely understand disease manifestation and state of the phenotype in the present time.” - Annie Evans, Director of R&D at Metabolon.
20 May 2020
Metabolomic insights will support Army’s research into Warfighter health-readiness and optimal performance. Metabolon, Inc., the global leader in metabolomics, has been selected by the U.S. Army Research Institute of Environmental Medicine (USARIEM), to analyze the metabolic profiles of military personnel in a research program being conducted by the Military Nutrition Division.
Find Us at These Events
6 October 2020
Join over 800 scientific leaders at the flagship Cell Series UK, connecting regenerative medicine and bioprocessing experts to transform cell research and therapies.
21 September 2020
Visit us at booth 610 Connect with 2000+ global scientists, engineers and executives working across the entire spectrum of biopharmaceutical development and production.
IGES is the International Genetic Epidemiology Society, a scientific society concerned with “the study of genetic components in complex biological phenomena” according to James V. Neel, the founding President of the Society. The successful mapping of the human genome will greatly facilitate the study of health and disease in a manner that integrates both host and environmental factors.
27 May 2020
Join Metabolon’s Patricia Sheridan, Ph.D., Senior Study Director, Discovery & Translational Sciences, for a conversation with Dr. Heath on May 27th at 11:00 am EDT/13:00 CEST. They will be discussing some of the current work that ISB is doing to explore COVID-19 infections and how metabolomics can be used to understand the pathophysiology of the infection.